Ashwagandha has become one of the most discussed supplements in the sleep and recovery space. The claims range from modest — it supports relaxation — to expansive — it improves sleep quality, reduces insomnia, and enhances recovery. Some of those claims have meaningful research behind them. Others are extrapolations from adjacent findings, and a few are simply marketing copy dressed as science.
This post examines what the clinical research on ashwagandha and sleep actually shows, what it doesn't show, and how to apply that accurately to a decision about whether to take it.
The Research Landscape: More Substantive Than Most Adaptogens
The first thing worth establishing is that ashwagandha has a more developed clinical evidence base than most of the adaptogen category. Ginseng, rhodiola, and schisandra are frequently marketed with similar claims and have significantly thinner trial records. Ashwagandha's research, while not without limitations, includes multiple randomised controlled trials with objective outcome measures in adult human populations.
That context matters because it changes the standard of evaluation. The question for ashwagandha is not "is there any evidence" — there is — but "what does the evidence specifically show, and does that match what it's being sold for."
What the Clinical Trials Actually Measured
The most frequently cited studies on ashwagandha and sleep have measured outcomes across several categories. Understanding which outcomes were measured — and which were not — is important for accurately interpreting the findings.
Subjective sleep quality scores. Most trials have used validated self-report questionnaires — primarily the Pittsburgh Sleep Quality Index (PSQI) — to measure participants' subjective experience of sleep quality. These are legitimate tools, but they measure how people feel about their sleep rather than what their sleep architecture is doing objectively. Subjective improvement is real and meaningful, but it is not the same as demonstrable change in deep sleep percentage, REM duration, or sleep efficiency.
Serum cortisol. Multiple trials have measured morning serum cortisol as a biomarker for HPA axis regulation. This is where the evidence for ashwagandha is most consistent and most mechanistically grounded. Reduced cortisol is the mechanism through which ashwagandha is hypothesised to improve sleep — if cortisol declines more appropriately in the evening, the conditions for deep sleep improve.
Perceived stress and anxiety scores. Validated tools including the Perceived Stress Scale have been used across multiple trials. Results are consistently positive — ashwagandha reliably reduces subjective stress in the research. Since elevated perceived stress is both a cause and consequence of poor sleep, this is a relevant outcome even if it doesn't directly measure sleep architecture.
Sleep onset latency and total sleep time. Some trials have measured these specifically. The findings are more variable than the subjective quality scores — some trials show statistically significant reductions in sleep onset latency, others show non-significant trends in the same direction.
The Specific Studies Worth Knowing
A 2019 randomised, double-blind, placebo-controlled trial published through research conducted at Asha Hospital in Hyderabad, India, examined the effects of ashwagandha root extract supplementation over ten weeks in adults with insomnia. The trial used both subjective measures and actigraphy — wrist-worn movement monitoring used as a proxy for sleep-wake patterns — making it more objective than pure self-report studies.
Findings: statistically significant improvements in sleep efficiency, total sleep time, sleep onset latency, and wake after sleep onset in the ashwagandha group compared to placebo. The effect sizes were moderate rather than dramatic, but they were consistent and statistically robust.
A separate trial published through the Indian Journal of Psychological Medicine examined ashwagandha's effects on stress and wellbeing in chronically stressed adults over eight weeks. The ashwagandha group showed significant reductions in serum cortisol — approximately 27 percent — alongside significant improvements in sleep quality scores and subjective wellbeing compared to placebo.
Research from the National Institute of Mental Health and Neurosciences in India has also examined ashwagandha's effects on sleep architecture in a smaller trial using polysomnography — formal sleep lab measurement. Results showed improvements in slow-wave sleep duration and sleep quality scores, though the small sample size limits the strength of conclusions drawn.
The collective picture from these and related studies, including work conducted at several Japanese research institutions, is consistent: ashwagandha supplementation over eight to twelve weeks produces statistically significant improvements in sleep quality measures in stressed adults, with a probable mechanism running through cortisol reduction and HPA axis modulation.
What the Research Doesn't Show
Being accurate about the evidence means being equally clear about what it doesn't demonstrate.
The research is not on healthy, non-stressed adults. Most trials have enrolled participants selected specifically for elevated stress, anxiety, or sleep complaints. The findings may not extrapolate to people with low baseline stress and good sleep who are taking ashwagandha as a performance supplement rather than as a stress correction.
Effect sizes are moderate, not dramatic. Ashwagandha improves sleep quality in the research — but the improvements are meaningful increments, not transformations. People entering trials with PSQI scores in the moderate-to-severe range show meaningful movement toward normal range scores. People with mild sleep complaints are likely to see smaller effects.
Most trials use proprietary extracts. The majority of positive research uses standardised root extracts — KSM-66® and Sensoril® are the most frequently studied commercial extracts. Generic ashwagandha powder or unstandardised extracts have a substantially thinner evidence base and may not deliver equivalent withanolide concentrations. The research cannot be extrapolated to all ashwagandha products.
The cortisol findings have variability. While the direction of cortisol change is consistently downward across trials, the magnitude varies considerably — from modest to substantial reductions. Individual response varies with baseline HPA axis status, stress load, and other factors that clinical trials partially control for but real-world use does not.
Long-term data is limited. Most trials run eight to twelve weeks. The sustained effects of ashwagandha supplementation beyond that window are less well-characterised. Whether benefits persist, require continued supplementation, or represent durable HPA axis recalibration is not yet clearly established.
The Form and Dose Question
The evidence base for ashwagandha is built predominantly on root extract standardised for withanolide content — not whole herb, not leaf extract, not unspecified powder. This matters because the pharmacologically active compounds — withanolides — vary significantly in concentration depending on the part of the plant used and the extraction process applied.
KSM-66® is the most clinically researched root-only extract, standardised to a minimum of 5% withanolides. The trials using KSM-66® have produced the most consistent positive results across multiple outcome measures. Sensoril® is a root-and-leaf extract with a different withanolide profile and separate, also positive, research base.
The dose used in most positive trials ranges from 300mg to 600mg of the standardised extract daily. Products containing significantly lower doses of unspecified ashwagandha extract cannot claim equivalence to the research findings.
An important accuracy note: the dose in Moongreens is below the upper end of the range used in clinical trials. This is stated transparently because the mechanism is real and the direction of effect is consistent even at lower doses — but the magnitude of effect at any specific dose varies by individual, and overstating equivalence to full clinical trial doses would be inaccurate.
What Ashwagandha Is and Isn't for Sleep
Based on the available evidence, an accurate characterisation of ashwagandha's role in sleep is as follows.
Ashwagandha is an effective intervention for stress-related sleep impairment in adults with elevated baseline cortisol or perceived stress. The mechanism — HPA axis modulation reducing nocturnal cortisol and improving the hormonal conditions for deep sleep — is well-supported. The clinical evidence shows consistent improvements in subjective sleep quality, cortisol levels, and sleep efficiency over eight to twelve weeks of consistent use with a standardised root extract.
It is not an acute sleep aid. It does not produce sedation. It does not directly induce sleep. Its effects accumulate over weeks rather than producing a noticeable change on any given night. It is most relevant for people whose sleep problem involves elevated stress or cortisol — which describes a large proportion of high-output professionals and athletes — and less relevant for people whose sleep problem is primarily circadian timing or non-stress-related insomnia.
For the target population of Moongreens — professionals, athletes, and high performers carrying sustained physical and psychological load — ashwagandha addresses a highly prevalent mechanism. KSM-66® is included in the Moongreens formula specifically because it is the most consistently studied extract in the evidence base, paired with Albion® magnesium bisglycinate for the complementary GABA pathway mechanism. The two together address both the neurological and hormonal conditions that govern sleep depth — which is why the combination is more complete than either alone.
The Practical Takeaway
If you're evaluating ashwagandha for sleep, the evidence supports its use under specific conditions: you are experiencing stress-related sleep impairment, you use a standardised root extract at an adequate dose, and you evaluate effect over a minimum of eight weeks rather than the first few days.
The research is more substantive than most adaptogens and less definitive than pharmaceutical sleep interventions. It sits in the category of well-evidenced nutritional support for a specific mechanism — not a cure, not a miracle, but a genuine and increasingly well-documented tool for the right problem.
Understanding what the research actually says — rather than what the marketing extrapolates from it — is what allows you to use it correctly and evaluate whether it's working for your specific situation.
Ashwagandha doesn't make you sleep better by telling your body to sleep — it makes you sleep better by convincing your stress system to stand down.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.